As of March 23, 2026, Sagimet Biosciences's top three insider holders are Partners 13, Limited Partnership Nea (TenPercentOwner, 3.00Mn shares), Enterprise Associates 13 Lp New (TenPercentOwner, 3.00Mn shares), Pbd Associates, Llc Kpcb (TenPercentOwner, 1.90Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Enterprise Associates 13 Lp New | 3,850,275 | 0 | 20 Jul, 2023 | |
| Partners 13, Limited Partnership Nea | 0 | 3,000,275 | 31 Jan, 2024 | |
| Enterprise Associates 13 Lp New | 3,000,275 | 0 | 31 Jan, 2024 | |
| Pbd Associates, Llc Kpcb | 0 | 1,899,475 | 20 Jul, 2023 | |
| Jinzi Jason Wu | 0 | 1,654,701 | 20 Jul, 2023 | |
| David Happel | President Ceo | 805,621 | 0 | 20 Feb, 2026 |
| Elizabeth Rozek | Chief Legal Admin. Officer | 234,959 | 0 | 20 Feb, 2026 |
| Eduardo Bruno Martins | Chief Medical Officer | 147,296 | 0 | 20 Feb, 2026 |
| George Kemble | Executive Chairman | 81,005 | 0 | 21 Nov, 2025 |
| Thierry Chauche | Chief Financial Officer | 59,688 | 0 | 20 Feb, 2026 |
| Merdad Parsey | 12,794 | 0 | 20 Jul, 2023 | |
| Forest Baskett | 0 | 11,300 | 31 Jan, 2024 | |
| Forest Baskett | 0 | 11,300 | 31 Jan, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Feb, 2026 | Eduardo Bruno Martins | Series A Common Stock | A | 44,000 | $0.00 | 147,296 | D | A |
| 19 Feb, 2026 | Thierry Chauche | Series A Common Stock | A | 44,000 | $0.00 | 59,688 | D | A |
| 19 Feb, 2026 | David Happel | Series A Common Stock | A | 128,000 | $0.00 | 805,621 | D | A |
| 19 Feb, 2026 | Elizabeth Rozek | Series A Common Stock | A | 44,000 | $0.00 | 234,959 | D | A |
| 19 Feb, 2026 | Eduardo Bruno Martins | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 19 Feb, 2026 | Thierry Chauche | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 19 Feb, 2026 | David Happel | Stock Option (Right to Buy) | A | 256,000 | $0.00 | 256,000 | D | A |
| 19 Feb, 2026 | Elizabeth Rozek | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 10 Feb, 2026 | Eduardo Bruno Martins | Series A Common Stock | D | 3,640 | $5.36 | 103,296 | D | S |
| 10 Feb, 2026 | Thierry Chauche | Series A Common Stock | D | 1,312 | $5.36 | 15,688 | D | S |
| 10 Feb, 2026 | Elizabeth Rozek | Series A Common Stock | D | 2,622 | $5.36 | 190,959 | D | S |
| 10 Feb, 2026 | David Happel | Series A Common Stock | D | 12,101 | $5.36 | 677,621 | D | S |
| 20 Nov, 2025 | George Kemble | Series A Common Stock | D | 37,688 | $7.69 | 81,005 | D | S |
| 04 Nov, 2025 | Elizabeth Rozek | Series A Common Stock | A | 9,855 | $0.00 | 193,581 | D | A |
| 04 Nov, 2025 | Elizabeth Rozek | Stock Option (Right to Buy) | A | 13,367 | $0.00 | 13,367 | D | A |
| 21 Jul, 2025 | David Happel | Series A Common Stock | D | 65,478 | $9.13 | 689,722 | D | S |
| 21 Jul, 2025 | Eduardo Bruno Martins | Series A Common Stock | D | 8,277 | $9.13 | 106,936 | D | S |
| 21 Jul, 2025 | Elizabeth Rozek | Series A Common Stock | D | 10,780 | $9.13 | 183,726 | D | S |
| 09 Jun, 2025 | Timothy P Walbert | Stock Option (Right to Buy) | A | 32,250 | $0.00 | 32,250 | D | A |
| 09 Jun, 2025 | Paul W. Hoelscher | Stock Option (Right to Buy) | A | 32,250 | $0.00 | 32,250 | D | A |